Drago®:一个创新的移动应用程序,以提高依从性和依从性的屋尘螨过敏原免疫治疗

Luciana Kase Tanno , Pham Thao Van Luong , Éric Fromentin , Édouard Sève , Mickaël Poulequin , Hoai-Bich Trinh , Julien Cottet , Pascal Demoly
{"title":"Drago®:一个创新的移动应用程序,以提高依从性和依从性的屋尘螨过敏原免疫治疗","authors":"Luciana Kase Tanno ,&nbsp;Pham Thao Van Luong ,&nbsp;Éric Fromentin ,&nbsp;Édouard Sève ,&nbsp;Mickaël Poulequin ,&nbsp;Hoai-Bich Trinh ,&nbsp;Julien Cottet ,&nbsp;Pascal Demoly","doi":"10.1016/j.jahd.2025.100041","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>House dust mite (HDM) allergens constitute the most frequent cause of persistent allergic rhinitis and asthma. Allergen immunotherapy (AIT) is the only disease-modifying treatment for patients suffering from IgE-mediated allergic conditions. The Drago® application is a free application to optimize the use of AIT through education modules, timing track and implementation of adherence based on games and avatar evolution.</div></div><div><h3>Methods</h3><div>Consecutive patients were offered to voluntarily use the application simultaneously to their AIT. We evaluated data related to patients’ adherence to HDM AIT over 3 years. Data generated were anonymized and stored following the French regulations. Compliance referred to the ratio of the number of doses taken by the patient to the duration of APP use by the patient, expressed as a percentage. Adherence was measured by comparing measured persistence (duration between the last date of the application use and starting date of treatment) with ideally expected persistence. Quality of life (QoL), Allergic Rhinitis Control Test (ARCT) and Global Initiative for Asthma (GINA) control scores have been evaluated at three different time points: the first, second, and third years of application use).</div></div><div><h3>Results</h3><div>From overall 4,906 users after 3 years of launch, 2,490 (50.7 %) were undergoing HDM AIT, with 244,200 numbers of accesses to the Drago® application. Mean age of users was 21 years, most of patients were children (74.6 %). Number of accesses overtime by children were proportionally higher than by adults and adolescents. Over 80 % percent of patients used the application from 7:00 to 10:00 AM (27.2 %) and from 18:00 to 21:00 PM (53.7 %). At year 3, mean rate of compliance over a period of three years was 45 % (confidence interval [CI]: 44.1 %–46.1 %), mean persistence was estimated in 327 days (CI: 315–337 days), with 76 % of mean percentage adherence (CI: 74.9 %–76.7 %). Persistence and adherence were significantly higher in children, but compliance was more significant in adults. We observed significant improvements in the mean ARCT, and QoL scores across three time points (first year, second year and third year).</div></div><div><h3>Conclusion</h3><div>Positive impact on adherence, persistence and burden of respiratory diseases were observed in patients using Drago® application and undergoing HDM AIT, in particular in childhood. Consolidating the presented data with the English version of Drago® application will soon be available.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"6 ","pages":"Article 100041"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Drago®: An innovative mobile application to improve adherence and complience of house dust mite allergen immunotherapy\",\"authors\":\"Luciana Kase Tanno ,&nbsp;Pham Thao Van Luong ,&nbsp;Éric Fromentin ,&nbsp;Édouard Sève ,&nbsp;Mickaël Poulequin ,&nbsp;Hoai-Bich Trinh ,&nbsp;Julien Cottet ,&nbsp;Pascal Demoly\",\"doi\":\"10.1016/j.jahd.2025.100041\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>House dust mite (HDM) allergens constitute the most frequent cause of persistent allergic rhinitis and asthma. Allergen immunotherapy (AIT) is the only disease-modifying treatment for patients suffering from IgE-mediated allergic conditions. The Drago® application is a free application to optimize the use of AIT through education modules, timing track and implementation of adherence based on games and avatar evolution.</div></div><div><h3>Methods</h3><div>Consecutive patients were offered to voluntarily use the application simultaneously to their AIT. We evaluated data related to patients’ adherence to HDM AIT over 3 years. Data generated were anonymized and stored following the French regulations. Compliance referred to the ratio of the number of doses taken by the patient to the duration of APP use by the patient, expressed as a percentage. Adherence was measured by comparing measured persistence (duration between the last date of the application use and starting date of treatment) with ideally expected persistence. Quality of life (QoL), Allergic Rhinitis Control Test (ARCT) and Global Initiative for Asthma (GINA) control scores have been evaluated at three different time points: the first, second, and third years of application use).</div></div><div><h3>Results</h3><div>From overall 4,906 users after 3 years of launch, 2,490 (50.7 %) were undergoing HDM AIT, with 244,200 numbers of accesses to the Drago® application. Mean age of users was 21 years, most of patients were children (74.6 %). Number of accesses overtime by children were proportionally higher than by adults and adolescents. Over 80 % percent of patients used the application from 7:00 to 10:00 AM (27.2 %) and from 18:00 to 21:00 PM (53.7 %). At year 3, mean rate of compliance over a period of three years was 45 % (confidence interval [CI]: 44.1 %–46.1 %), mean persistence was estimated in 327 days (CI: 315–337 days), with 76 % of mean percentage adherence (CI: 74.9 %–76.7 %). Persistence and adherence were significantly higher in children, but compliance was more significant in adults. We observed significant improvements in the mean ARCT, and QoL scores across three time points (first year, second year and third year).</div></div><div><h3>Conclusion</h3><div>Positive impact on adherence, persistence and burden of respiratory diseases were observed in patients using Drago® application and undergoing HDM AIT, in particular in childhood. Consolidating the presented data with the English version of Drago® application will soon be available.</div></div>\",\"PeriodicalId\":100752,\"journal\":{\"name\":\"Journal of Allergy and Hypersensitivity Diseases\",\"volume\":\"6 \",\"pages\":\"Article 100041\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Allergy and Hypersensitivity Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2950312425000119\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Hypersensitivity Diseases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950312425000119","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

室内尘螨(HDM)过敏原是造成持续性变应性鼻炎和哮喘的最常见原因。过敏原免疫疗法(AIT)是唯一的疾病改善治疗的患者患有ige介导的过敏条件。Drago®应用程序是一个免费的应用程序,通过教育模块优化AIT的使用,定时跟踪和基于游戏和化身进化的遵守实施。方法连续患者自愿同时使用该应用程序。我们评估了患者在3年内坚持HDM AIT的相关数据。生成的数据是匿名的,并按照法国的规定进行存储。依从性是指患者服用的剂量数与患者使用APP的时间之比,以百分比表示。依从性是通过比较测量的持续时间(从最后应用使用日期到治疗开始日期之间的持续时间)和理想预期持续时间来衡量的。生活质量(QoL)、变应性鼻炎控制测试(ARCT)和全球哮喘倡议(GINA)控制评分在三个不同的时间点进行了评估:应用的第一年、第二年和第三年。结果在发布3年后的4906名用户中,2490名(50.7%)用户正在进行HDM AIT,访问Drago®应用程序的次数为24.42万次。平均年龄21岁,以儿童为主(74.6%)。儿童加班的人数比例高于成人和青少年。超过80%的患者在早上7:00到10:00(27.2%)和晚上18:00到21:00(53.7%)使用该应用程序。在第3年,三年内的平均依从率为45%(置信区间[CI]: 44.1% - 46.1%),平均持续时间估计为327天(CI: 315-337天),平均依从率为76% (CI: 74.9% - 76.7%)。儿童的坚持和依从性明显更高,但成人的依从性更显著。我们观察到三个时间点(第一年、第二年和第三年)的平均ARCT和生活质量评分有显著改善。结论使用Drago®贴剂并接受HDM AIT的患者,尤其是儿童患者,对依从性、持久性和呼吸系统疾病负担有积极影响。整合呈现的数据与英文版的Drago®应用程序将很快可用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Drago®: An innovative mobile application to improve adherence and complience of house dust mite allergen immunotherapy

Background

House dust mite (HDM) allergens constitute the most frequent cause of persistent allergic rhinitis and asthma. Allergen immunotherapy (AIT) is the only disease-modifying treatment for patients suffering from IgE-mediated allergic conditions. The Drago® application is a free application to optimize the use of AIT through education modules, timing track and implementation of adherence based on games and avatar evolution.

Methods

Consecutive patients were offered to voluntarily use the application simultaneously to their AIT. We evaluated data related to patients’ adherence to HDM AIT over 3 years. Data generated were anonymized and stored following the French regulations. Compliance referred to the ratio of the number of doses taken by the patient to the duration of APP use by the patient, expressed as a percentage. Adherence was measured by comparing measured persistence (duration between the last date of the application use and starting date of treatment) with ideally expected persistence. Quality of life (QoL), Allergic Rhinitis Control Test (ARCT) and Global Initiative for Asthma (GINA) control scores have been evaluated at three different time points: the first, second, and third years of application use).

Results

From overall 4,906 users after 3 years of launch, 2,490 (50.7 %) were undergoing HDM AIT, with 244,200 numbers of accesses to the Drago® application. Mean age of users was 21 years, most of patients were children (74.6 %). Number of accesses overtime by children were proportionally higher than by adults and adolescents. Over 80 % percent of patients used the application from 7:00 to 10:00 AM (27.2 %) and from 18:00 to 21:00 PM (53.7 %). At year 3, mean rate of compliance over a period of three years was 45 % (confidence interval [CI]: 44.1 %–46.1 %), mean persistence was estimated in 327 days (CI: 315–337 days), with 76 % of mean percentage adherence (CI: 74.9 %–76.7 %). Persistence and adherence were significantly higher in children, but compliance was more significant in adults. We observed significant improvements in the mean ARCT, and QoL scores across three time points (first year, second year and third year).

Conclusion

Positive impact on adherence, persistence and burden of respiratory diseases were observed in patients using Drago® application and undergoing HDM AIT, in particular in childhood. Consolidating the presented data with the English version of Drago® application will soon be available.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信